|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| Malignant Melanoma | |||||
| 2 | Additional conditions recognized in this trial | ||||
| Melanoma | |||||
| 3 | More general conditions related to this trial | ||||
| Neoplasms | |||||
| Neoplasms by Histologic Type | |||||
| Neoplasms, Germ Cell and Embryonal | |||||
| Neoplasms, Nerve Tissue | |||||
| Neuroectodermal Tumors | |||||
| Neuroendocrine Tumors | |||||
| Nevi and Melanomas | |||||
| 4 | Interventions listed in this trial | ||||
| HyperAcute-Melanoma Vaccine | |||||
| HyperAcute- Melanoma Vaccine | |||||
| 5 | Sponsors listed in this trial | ||||
| NewLink Genetics Corporation | |||||